Alyce Raises $30M in Series B Funding
20 Apr, 2021
– Variantyx, a Boston, MA-based hereditary disease testing company, secured $20M in Series C funding.
– The round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango Venture Capital, New Era Capital Partners, 20/20 HealthCare Partners.
– In conjunction with the funding, Zafrira Avnur, PhD, Quark Venture Chief Scientific Officer & Partner, will join the Variantyx board of directors.
– The company intends to use the funds for development of its tumor diagnostic solutions and the expansion of sales.